Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT T NAISMITH

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1871519090
CMS profile
356985
Location
SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$149,649.25

64 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI US SERVICES INC. $41,359.50 16
GENZYME CORPORATION $31,856.14 14
H. Lundbeck A S $19,433.00 4
Horizon Therapeutics plc $15,969.00 7
Genentech USA, Inc. $10,697.36 5
Biogen, Inc. $7,486.25 3
Celgene Corporation $6,160.00 5
E.R. Squibb & Sons, L.L.C. $3,840.00 1
Greenwich Biosciences, Inc. $3,808.00 1
Janssen Pharmaceuticals, Inc $3,225.00 3
BeiGene USA, Inc. $2,375.00 1
TG THERAPEUTICS, INC. $1,940.00 1
BANNER LIFE SCIENCES, LLC $900.00 1
Cello Health Advantage Inc $450.00 1
Alexion Pharmaceuticals, Inc. $150.00 1

Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT T NAISMITH

NPI 1871519090 · CMS profile ID 356985

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871519090?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT T NAISMITH, NPI 1871519090, CMS profile ID 356985. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871519090?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ROBERT T NAISMITH, NPI 1871519090, CMS profile ID 356985. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871519090?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ROBERT T NAISMITH, NPI 1871519090, CMS profile ID 356985, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–64 of 64 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1871519090?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

64 matching records · $149,649.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 64 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–64 of 64.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $2,966.2504/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827856257 CMS
Celgene Corporation $1,550.0003/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783713209 CMS
Celgene Corporation $600.0003/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783713225 CMS
Horizon Therapeutics plc $1,560.0003/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797177831 CMS
SANOFI US SERVICES INC. $3,549.0003/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843520279 CMS
SANOFI US SERVICES INC. $273.0003/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843520281 CMS
H. Lundbeck A S $4,333.0003/01/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853089063 CMS
Alexion Pharmaceuticals, Inc. $150.0002/23/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783112127 CMS
Horizon Therapeutics plc $1,560.0002/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797177829 CMS
SANOFI US SERVICES INC. $2,320.5002/16/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843520283 CMS
SANOFI US SERVICES INC. $409.5002/16/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843520285 CMS
Celgene Corporation $600.0001/19/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783713227 CMS
Horizon Therapeutics plc $1,560.0001/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797177827 CMS
SANOFI US SERVICES INC. $1,911.0001/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843520287 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $71,980.23 89
PY2020 $18,637.75 11
PY2021 $149,649.25 64
PY2022 $128,125.36 88
PY2023 $83,098.46 54
PY2024 $79,089.46 65
PY2025 $145,927.31 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,200.23 5
PY2025 Principal investigator $2,304,911.33 175
PY2024 Recipient $4,169.56 2
PY2024 Principal investigator $1,833,978.11 198
PY2023 Recipient $1,207.30 1
PY2023 Principal investigator $2,285,062.52 172
PY2022 Principal investigator $1,952,980.53 75
PY2021 Recipient $1,493.31 2
PY2021 Principal investigator $1,571,955.65 87
PY2020 Recipient $15,895.02 8
PY2020 Principal investigator $1,519,008.65 88
PY2019 Recipient $1,934.04 6
PY2019 Principal investigator $1,676,387.92 183

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

180 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $11,500.00 12/15/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211684120
Principal investigator 1 Genentech, Inc. $150.00 12/15/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211684126
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,050.00 12/11/2025 Non-covered Recipient Entity
Washington University
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1235991837
Principal investigator 1 Genentech, Inc. $1,796.00 12/09/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684130
Principal investigator 1 Genentech, Inc. $28,476.00 12/04/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Satralizumab in MOG AD No dispute reported 06/30/2026 1211683992
Principal investigator 1 Genentech, Inc. $26,832.00 12/04/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211684128
Principal investigator 1 Genentech, Inc. $8,564.00 12/03/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211684512
Principal investigator 1 Genentech, Inc. $1,660.00 11/27/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211684392
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $18,148.00 11/24/2025 Non-covered Recipient Entity
Washington University
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1235991839
Principal investigator 1 Genentech, Inc. $150.00 11/20/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684110
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $361,812.12 11/19/2025 Non-covered Recipient Entity
Washington University
A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) No dispute reported 06/30/2026 1235991835
Principal investigator 1 Genentech, Inc. $300.00 11/18/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211684118
Principal investigator 1 Genentech, Inc. $24,185.00 11/13/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684116
Principal investigator 1 Genentech, Inc. $4,764.00 11/12/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
OCARINA I No dispute reported 06/30/2026 1211684114
Principal investigator 1 Genentech, Inc. $4,750.00 11/10/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
OCARINA I No dispute reported 06/30/2026 1211684112
Principal investigator 1 Genentech, Inc. $516.00 11/05/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Satralizumab in MOG AD No dispute reported 06/30/2026 1211683990
Principal investigator 1 Genentech, Inc. $63,904.00 10/28/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684104
Principal investigator 1 Genentech, Inc. $23,722.00 10/28/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684106
Principal investigator 1 Genentech, Inc. $5,598.00 10/15/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684102
Principal investigator 1 Genentech, Inc. $2,500.00 10/15/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Ph 1 of P-CD19CD20-ALLO1 in Multiple Sclerosis No dispute reported 06/30/2026 1211684504
Principal investigator 1 Celgene Corporation $20,075.00 10/02/2025 Non-covered Recipient Entity
Washington University
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1222306681
Principal investigator 1 F. Hoffmann-La Roche AG $261.00 10/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684344
Principal investigator 1 F. Hoffmann-La Roche AG $450.00 10/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684346
Principal investigator 1 F. Hoffmann-La Roche AG $211.00 10/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684348
Principal investigator 1 F. Hoffmann-La Roche AG $68.00 10/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684350
Principal investigator 1 F. Hoffmann-La Roche AG $5,705.00 10/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684352
Principal investigator 1 F. Hoffmann-La Roche AG $340.00 10/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684354
Principal investigator 1 F. Hoffmann-La Roche AG $5,100.00 10/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684356
Principal investigator 1 Genentech, Inc. $4,164.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Satralizumab in MOG AD No dispute reported 06/30/2026 1211683986
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,370.00 10/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190303455
Recipient Novartis Pharma AG $18.62 09/25/2025 Covered Recipient Physician COMB157Q12301 No dispute reported 06/30/2026 1248109575
Principal investigator 1 F. Hoffmann-La Roche AG $313.00 09/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684276
Principal investigator 1 F. Hoffmann-La Roche AG $13,230.00 09/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684280
Principal investigator 1 F. Hoffmann-La Roche AG $12,135.00 09/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684296
Principal investigator 1 F. Hoffmann-La Roche AG $12,135.00 09/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684324
Principal investigator 1 F. Hoffmann-La Roche AG $6,412.00 09/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684330
Principal investigator 1 F. Hoffmann-La Roche AG $6,412.00 09/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684336
Principal investigator 1 Genentech, Inc. $180.00 09/22/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211684098
Principal investigator 1 Genentech, Inc. $14,525.00 09/19/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211684082
Principal investigator 1 Genentech, Inc. $14,525.00 09/18/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211684096
Principal investigator 1 Genentech, Inc. $1,233.00 09/17/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684094
Principal investigator 1 F. Hoffmann-La Roche AG $13,230.00 09/15/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684282
Principal investigator 1 F. Hoffmann-La Roche AG $13,012.00 09/15/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684288
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 09/15/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684312
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 09/15/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684314
Principal investigator 1 F. Hoffmann-La Roche AG $13,230.00 09/15/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684318
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 09/15/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684320
Principal investigator 1 F. Hoffmann-La Roche AG $6,412.00 09/15/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684326
Principal investigator 1 F. Hoffmann-La Roche AG $13,012.00 09/15/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684328
Principal investigator 1 F. Hoffmann-La Roche AG $13,230.00 09/15/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684338
Principal investigator 1 F. Hoffmann-La Roche AG $13,230.00 09/15/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684340
Principal investigator 1 Genentech, Inc. $5,473.80 09/10/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211684388
Principal investigator 1 Genentech, Inc. $204.00 09/04/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Satralizumab in MOG AD No dispute reported 06/30/2026 1211683984
Principal investigator 1 Genentech, Inc. $5,025.00 08/26/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211684088
Principal investigator 1 Genentech, Inc. $11,740.00 08/26/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211684090
Principal investigator 1 Genentech, Inc. $10,995.00 08/20/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
OCARINA I No dispute reported 06/30/2026 1211684086
Principal investigator 1 Genentech, Inc. $103,355.00 08/19/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Satralizumab in MOG AD No dispute reported 06/30/2026 1211683988
Principal investigator 1 Genentech, Inc. $13,879.00 08/18/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684092
Principal investigator 1 Genentech, Inc. $10,332.00 08/15/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211684084
Principal investigator 1 Genentech, Inc. $22,362.00 08/04/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Satralizumab in MOG AD No dispute reported 06/30/2026 1211683980
Principal investigator 1 Celgene Corporation $45,834.00 08/01/2025 Non-covered Recipient Entity
Washington University
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1222306575
Principal investigator 1 Genentech, Inc. $9,561.96 08/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211684376
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,041.39 07/28/2025 Non-covered Recipient Entity
Washington University School Of Medicine Cardiovascular Division
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1235991778
Principal investigator 1 F. Hoffmann-La Roche AG $13,230.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684274
Principal investigator 1 F. Hoffmann-La Roche AG $1,020.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684278
Principal investigator 1 F. Hoffmann-La Roche AG $300.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684284
Principal investigator 1 F. Hoffmann-La Roche AG $1,175.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684286
Principal investigator 1 F. Hoffmann-La Roche AG $174.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684290
Principal investigator 1 F. Hoffmann-La Roche AG $1,175.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684292
Principal investigator 1 F. Hoffmann-La Roche AG $1,224.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684294
Principal investigator 1 F. Hoffmann-La Roche AG $48.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684298
Principal investigator 1 F. Hoffmann-La Roche AG $6,412.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684300
Principal investigator 1 F. Hoffmann-La Roche AG $600.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684302
Principal investigator 1 F. Hoffmann-La Roche AG $13,012.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684304
Principal investigator 1 F. Hoffmann-La Roche AG $348.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684306
Principal investigator 1 F. Hoffmann-La Roche AG $12,938.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684308
Principal investigator 1 F. Hoffmann-La Roche AG $6,412.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684316
Principal investigator 1 F. Hoffmann-La Roche AG $1,500.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684322
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684334
Principal investigator 1 F. Hoffmann-La Roche AG $1,835.00 07/23/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684342
Principal investigator 1 Genentech, Inc. $19,086.00 07/21/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684080
Principal investigator 1 Alexion Pharmaceuticals, Inc. $2,020.00 07/16/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT) No dispute reported 06/30/2026 1185543284
Principal investigator 1 Genentech, Inc. $7,144.00 07/08/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211684380
Principal investigator 1 Genentech, Inc. $26,851.00 07/07/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Satralizumab in MOG AD No dispute reported 06/30/2026 1211683982
Principal investigator 1 F. Hoffmann-La Roche AG $261.00 07/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684310
Principal investigator 1 F. Hoffmann-La Roche AG $450.00 07/02/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684332
Principal investigator 1 Genentech, Inc. $58,985.00 07/02/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Satralizumab in MOG AD No dispute reported 06/30/2026 1211683966
Principal investigator 1 Genentech, Inc. $4,244.00 07/02/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211684032
Principal investigator 1 Genentech, Inc. $4,472.00 07/02/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211684036
Principal investigator 1 Genentech, Inc. $7,066.00 06/23/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211684028
Recipient Novartis Pharma AG $94.11 06/23/2025 Covered Recipient Physician COMB157Q12301 No dispute reported 06/30/2026 1248109835
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 06/20/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684260
Principal investigator 1 Genentech, Inc. $76.00 06/18/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211684030
Principal investigator 1 Genentech, Inc. $10,017.48 06/13/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211684368
Principal investigator 1 Genentech, Inc. $769.20 06/11/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684040
Principal investigator 1 Genentech, Inc. $2,638.00 06/10/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211684024
Principal investigator 1 Genentech, Inc. $1,129.00 06/10/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684042
Principal investigator 1 Genentech, Inc. $382.00 06/04/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Satralizumab in MOG AD No dispute reported 06/30/2026 1211683964
Principal investigator 1 Genentech, Inc. $37,411.00 06/03/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211684034
Principal investigator 1 Genentech, Inc. $11,410.00 06/02/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684026
Principal investigator 1 F. Hoffmann-La Roche AG $313.00 05/27/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684244
Principal investigator 1 F. Hoffmann-La Roche AG $313.00 05/27/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684246
Principal investigator 1 F. Hoffmann-La Roche AG $313.00 05/27/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684248
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 05/27/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684252
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 05/27/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684254
Principal investigator 1 F. Hoffmann-La Roche AG $313.00 05/27/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684256
Principal investigator 1 F. Hoffmann-La Roche AG $313.00 05/27/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684262
Principal investigator 1 F. Hoffmann-La Roche AG $6,412.00 05/27/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684264
Principal investigator 1 Genentech, Inc. $10,229.00 05/27/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
OCARINA I No dispute reported 06/30/2026 1211684038
Principal investigator 1 Genentech, Inc. $1,920.00 05/14/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684072
Principal investigator 1 Genentech, Inc. $81,264.00 05/09/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684062
Principal investigator 1 Genentech, Inc. $4,551.00 05/08/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Satralizumab in MOG AD No dispute reported 06/30/2026 1211683978
Principal investigator 1 Genentech, Inc. $17,493.00 05/08/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
OCARINA I No dispute reported 06/30/2026 1211684074
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,698.89 04/30/2025 Non-covered Recipient Entity
Washington University School Of Medicine Cardiovascular Division
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1235991776
Principal investigator 1 Genentech, Inc. $1,319.00 04/29/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211684064
Principal investigator 1 F. Hoffmann-La Roche AG $313.00 04/25/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684250
Principal investigator 1 F. Hoffmann-La Roche AG $13,012.00 04/25/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684258
Principal investigator 1 F. Hoffmann-La Roche AG $13,012.00 04/25/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684266
Principal investigator 1 F. Hoffmann-La Roche AG $6,412.00 04/25/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684268
Principal investigator 1 F. Hoffmann-La Roche AG $313.00 04/25/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684270
Principal investigator 1 F. Hoffmann-La Roche AG $313.00 04/25/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684272
Principal investigator 1 Genentech, Inc. $6,550.00 04/16/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211684060
Principal investigator 1 Genentech, Inc. $6,983.00 04/16/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211684070
Principal investigator 1 Genentech, Inc. $14,525.00 04/15/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211684066
Recipient Novartis Pharma AG $487.50 04/15/2025 Covered Recipient Physician COMB157Q12301 No dispute reported 06/30/2026 1248109577
Principal investigator 1 Alexion Pharmaceuticals, Inc. $2,060.00 04/14/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE
A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT) No dispute reported 06/30/2026 1185543286
Principal investigator 1 Genentech, Inc. $1,504.00 04/14/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Satralizumab in MOG AD No dispute reported 06/30/2026 1211683976
Principal investigator 1 Genentech, Inc. $96,041.00 04/11/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Satralizumab in MOG AD No dispute reported 06/30/2026 1211683972
Principal investigator 1 Genentech, Inc. $103.00 04/11/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Satralizumab in MOG AD No dispute reported 06/30/2026 1211683974
Principal investigator 1 Genentech, Inc. $1,396.60 04/02/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211684068
Principal investigator 1 Genentech, Inc. $934.52 03/27/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211684358
Principal investigator 1 Genentech, Inc. $10,017.48 03/27/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211684360
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684192
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684194
Principal investigator 1 F. Hoffmann-La Roche AG $6,412.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684200
Principal investigator 1 F. Hoffmann-La Roche AG $313.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684202
Principal investigator 1 F. Hoffmann-La Roche AG $6,195.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684204
Principal investigator 1 F. Hoffmann-La Roche AG $6,195.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684206
Principal investigator 1 F. Hoffmann-La Roche AG $6,195.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684210
Principal investigator 1 F. Hoffmann-La Roche AG $6,412.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684212
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684214
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684220
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684228
Principal investigator 1 F. Hoffmann-La Roche AG $6,195.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684230
Principal investigator 1 F. Hoffmann-La Roche AG $13,012.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684232
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684236
Principal investigator 1 F. Hoffmann-La Roche AG $313.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684238
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684240
Principal investigator 1 F. Hoffmann-La Roche AG $6,195.00 03/21/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684242
Principal investigator 1 Genentech, Inc. $1,920.00 03/20/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211684056
Principal investigator 1 Genentech, Inc. $851.00 03/20/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
OCARINA I No dispute reported 06/30/2026 1211684058
Principal investigator 1 Genentech, Inc. $13,768.00 03/20/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211684076
Principal investigator 1 Genentech, Inc. $18,937.00 03/20/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684078
Recipient Novartis Pharma AG $2,275.00 03/18/2025 Covered Recipient Physician COMB157Q12301 No dispute reported 06/30/2026 1248109579
Principal investigator 1 F. Hoffmann-La Roche AG $600.00 03/12/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684216
Principal investigator 1 F. Hoffmann-La Roche AG $348.00 03/12/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684222
Principal investigator 1 Genentech, Inc. $240.00 02/26/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Satralizumab in MOG AD No dispute reported 06/30/2026 1211683970
Principal investigator 1 Genentech, Inc. $3,000.00 02/26/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211684044
Principal investigator 1 Alexion Pharmaceuticals, Inc. $2,125.00 02/25/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY IN SAINT LOUIS
A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT) No dispute reported 06/30/2026 1185543290
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,519.75 02/25/2025 Non-covered Recipient Entity
Washington University School Of Medicine Cardiovascular Division
A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) No dispute reported 06/30/2026 1235991774
Recipient Novartis Pharma AG $325.00 02/25/2025 Covered Recipient Physician COMB157Q12301 No dispute reported 06/30/2026 1248109581
Principal investigator 1 F. Hoffmann-La Roche AG $150.00 02/19/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684190
Principal investigator 1 F. Hoffmann-La Roche AG $5,705.00 02/19/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684208
Principal investigator 1 F. Hoffmann-La Roche AG $48.00 02/19/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684218
Principal investigator 1 F. Hoffmann-La Roche AG $87.00 02/19/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684234
Principal investigator 1 Celgene Corporation $212,224.56 02/12/2025 Non-covered Recipient Entity
Washington University
A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG) (Breakfree-2) No dispute reported 06/30/2026 1222306631
Principal investigator 1 Genentech, Inc. $48.00 02/07/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
OCARINA I No dispute reported 06/30/2026 1211684050
Principal investigator 1 Genentech, Inc. $16,863.00 02/06/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211684046
Principal investigator 1 Genentech, Inc. $1,195.00 01/29/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Satralizumab in MOG AD No dispute reported 06/30/2026 1211683968
Principal investigator 1 Genentech, Inc. $71,979.00 01/29/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211684048
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,226.00 01/28/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY IN SAINT LOUIS
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190310618
Principal investigator 1 F. Hoffmann-La Roche AG $6,195.00 01/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684188
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 01/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684196
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 01/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684198
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 01/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684224
Principal investigator 1 F. Hoffmann-La Roche AG $1,061.00 01/22/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211684226
Principal investigator 1 Alexion Pharmaceuticals, Inc. $86,248.20 01/16/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY IN SAINT LOUIS
A Phase 3, External Placebo Controlled, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) No dispute reported 06/30/2026 1185543288
Principal investigator 1 Genentech, Inc. $10,020.00 01/16/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
OCARINA I No dispute reported 06/30/2026 1211684054
Principal investigator 1 Genentech, Inc. $19,794.00 01/03/2025 Non-covered Recipient Entity
WASHINGTON UNIV SCHOOL OF MEDICINE CENTER FOR CLINICAL STUDIES
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211684052
Principal investigator 1 Novartis Pharmaceuticals Corporation $140,148.38 01/01/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190303457